Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk

被引：2

作者：

Sjolander, Annica ^{[1
,2
]}

Andersson, Malin E. ^{[2
]}

Zetterberg, Henrik ^{[2
]}

Minthon, Lennart ^{[3
,4
]}

Bogdanovic, Nenad ^{[5
]}

Blennow, Kaj ^{[2
]}

机构：

[1] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Clin Chem & Transfus Med, Sahlgrenska Acad,Inst Biomed, SE-41345 Gothenburg, Sweden

[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, SE-41345 Gothenburg, Sweden

[3] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Malmo, Sweden

[4] Malmo Univ Hosp, Neuropsychiat Clin, Malmo, Sweden

[5] Karolinska Univ Hosp Huddinge, Karolinska Inst, Sect Clin Geriatr, Neurotec Dept, Stockholm, Sweden

来源：

MOLECULAR MEDICINE REPORTS | 2009年 / 2卷 / 06期

关键词：

Alzheimer's disease; cyclin-dependent kinase 5; tau; beta-amyloid; apolipoprotein E; cerebrospinal fluid; biomarkers; plaque; tangle; PAIRED HELICAL FILAMENTS; CEREBROSPINAL-FLUID; TAU-PROTEIN; APOLIPOPROTEIN-E; STANDARDIZATION; BRAIN; BETA-AMYLOID((1-42)); NEURODEGENERATION; PHOSPHORYLATION; POLYMORPHISM;

D O I：

10.3892/mmr_00000203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cyclin-dependent kinase 5 (cdk5) has been identified as one of the kinases that phosphorylates tau at several Alzheimer's disease (AD)-associated sites. Cdk5 is predominantly expressed in neurons, and has higher activity in AD brains than in non-demented brains. To investigate the effect of the CDK5 gene on AD, we analyzed an SNP of the CDK5 gene (rs2069456) in 347 patients with AD and in 157 controls. CDK5 genetic data was investigated in subgroups in relation to biochemical and neuropathological markers for AD. We found no significant differences in genotype or allele distributions between AD patients and controls. None of the CDK5 gene variants influenced biomarkers for AD.

引用

页码：989 / 992

页数：4

共 50 条

[1] Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer's disease
Czapski, Grzegorz A.
Maruszak, Aleksandra
Styczynska, Maria
Zekanowski, Cezary
Safranow, Krzysztof
Strosznajder, Joanna B.
ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2012, 72 (04) : 397 - 411
[2] The Role of Cdk5 in Alzheimer's Disease
Liu, Shu-Lei
Wang, Chong
Jiang, Teng
Tan, Lan
Xing, Ang
Yu, Jin-Tai
MOLECULAR NEUROBIOLOGY, 2016, 53 (07) : 4328 - 4342
[3] The Role of Cdk5 in Alzheimer’s Disease
Shu-Lei Liu
Chong Wang
Teng Jiang
Lan Tan
Ang Xing
Jin-Tai Yu
Molecular Neurobiology, 2016, 53 : 4328 - 4342
[4] No association of CDK5 genetic variants with Alzheimer's disease risk
Vazquez-Higuera, Jose Luis
Mateo, Ignacio
Sanchez-Juan, Pascual
Rodriguez-Rodriguez, Eloy
Infante, Jon
Berciano, Jose
Combarros, Onofre
BMC MEDICAL GENETICS, 2009, 10
[5] Role of cdk5 in the pathogenesis of Alzheimer's disease
Lau, LF
Ahlijanian, MK
NEUROSIGNALS, 2003, 12 (4-5) : 209 - 214
[6] Cdk5 deregulation in the pathogenesis of Alzheimer's disease
Cruz, JC
Tsai, LH
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (09) : 452 - 458
[7] Cdk5, a therapeutic target for Alzheimer's disease?
Tsai, LH
Lee, MS
Cruz, J
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2004, 1697 (1-2): : 137 - 142
[8] CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Fukasawa, Josianne T.
de Labio, Roger W.
Rasmussen, Lucas T.
de Oliveira, Lucieni C.
Chen, Elizabeth
Villares, Joao
Tureck, Gustavo
Smith, Marilia de Arruda C.
Payao, Spencer L. M.
CURRENT ALZHEIMER RESEARCH, 2018, 15 (02) : 182 - 186
[9] Silencing of CDK5 as potential therapy for Alzheimer's disease
Lopez-Tobon, Alejandro
Fredy Castro-Alvarez, John
Piedrahita, Diego
Boudreau, Ryan L.
Carlos Gallego-Gomez, Juan
Patricia Cardona-Gomez, Gloria
REVIEWS IN THE NEUROSCIENCES, 2011, 22 (02) : 143 - 152
[10] Cdk5 as a drug target for the treatment of Alzheimer’s disease
Lit-Fui Lau
Patricia A. Seymour
Mark A. Sanner
Joel B. Schachter
Journal of Molecular Neuroscience, 2002, 19 : 267 - 273

← 1 2 3 4 5 →